Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma

被引:0
|
作者
Bennett, Charlotte [1 ]
Morgan, Sian [2 ]
Aboud, Karam [1 ]
Frazer, Ricky Dylan [1 ]
机构
[1] Velindre Univ NHS Trust, Oncol, Cardiff, Wales
[2] All Wales Med Genet Serv, Oncol, Cardiff, Wales
关键词
Skin cancer; Oncology; Malignant disease and immunosuppression; Cancer intervention;
D O I
10.1136/bcr-2022-254268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The identification of genetic variants in melanoma has enabled the development of targeted therapies. Under the National Institute for Health and Care Excellence (NICE) guidance, patients with BRAF V600E variant are eligible for BRAF and MEK inhibitor therapy. For those with advanced or highly symptomatic disease, a rapid response to treatment is often seen. Current practice relies on tissue biopsy to perform immunohistochemistry (IHC) or next generation sequencing (NGS) to identify these variants; however, this can take up to 2 weeks. In patients with widespread disease, rapid initiation of treatment can be lifesaving.We describe a case in which hotspot circulating tumour DNA (ctDNA) analysis confirmed BRAF variant 6 days prior to biopsy results. This was utilised to expedite treatment initiation and symptomatically, the patient had initial improvement within a few days.This article demonstrates the potential value of ctDNA analysis and the need for further research into this as an alternative to NGS for patients with rapidly progressive disease.
引用
收藏
页数:3
相关论文
共 50 条
  • [41] BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry
    Yaman, Banu
    Kandiloglu, Gulsen
    Akalin, Taner
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2016, 38 (02) : 113 - 120
  • [42] Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline
    Knol, Anne C.
    Vallee, Audrey
    Herbreteau, Guillaume
    Nguyen, Jean-Michel
    Varey, Emilie
    Gaultier, Aurelie
    Theoleyre, Sandrine
    Saint-Jean, Melanie
    Peuvrel, Lucie
    Brocard, Anabelle
    Quereux, Gaelle
    Khammari, Amir
    Denis, Marc G.
    Dreno, Brigitte
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (10) : 783 - 788
  • [43] Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib
    Kromer, Christian
    Vlahova, Lyubomira D.
    Julius, Katharina
    Schnabel, Viktor
    Schoen, Michael P.
    Reuter-Jessen, Kirsten
    Seif Amir Hosseini, Ali
    Kretschmer, Lutz
    MELANOMA RESEARCH, 2022, 32 (02) : 124 - 127
  • [44] Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?
    Cybulska-Stopa, Bozena
    Czarnecka, Anna Malgorzata
    Ostaszewski, Krzysztof
    Piejko, Karolina
    Zietek, Marcin
    Dziura, Robert
    Rutkowska, Ewa
    Galus, Lukasz
    Calik, Jacek
    Salek-Zan, Agata
    Zemelka, Tomasz
    Kamycka, Agnieszka
    Bal, Wieslaw
    Kubiatowski, Tomasz
    Rogala, Pawel
    Switaj, Tomasz
    Kaminska-Winciorek, Grazyna
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma
    Long, G. V.
    Menzies, A. M.
    Nagrial, A.
    Haydu, L.
    Hamilton, A. L.
    Mann, G.
    Hughes, T. M.
    Thompson, J. F.
    Scolyer, R. A.
    Kefford, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Prevalence of BRAF V600E mutation in metastatic melanoma of Mexican Mestizo population
    Ruiz-Garcia, E.
    Meneses, A.
    Martinez-Said, H.
    Aguilar-Ponce, J. L.
    Mohar, A.
    Lopez, A.
    Alonso-Luna, O.
    Guadarrama-Orozco, J. A.
    Green, D.
    Astudillo-de la Vega, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S875 - S875
  • [47] Comparison of different testing methods for detection of BRAF V600 mutation in metastatic melanoma
    Hernandez-Losa, J.
    Ruano, Y.
    Trigo Sanchez, I.
    Somoza, R.
    Ferrer, B.
    Garcia Verdes-Montenegro, F.
    Urech, M.
    Ramon Y Cajal, S.
    Rios Martin, J. J.
    Rodriguez-Peralto, J. L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis
    Tembe, Varsha
    Schramm, Sarah-Jane
    Stark, Mitchell S.
    Patrick, Ellis
    Jayaswal, Vivek
    Tang, Yue Hang
    Barbour, Andrew
    Hayward, Nicholas K.
    Thompson, John F.
    Scolyer, Richard A.
    Yang, Yee Hwa
    Mann, Graham J.
    PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (03) : 254 - 266
  • [49] BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
    Scolyer, Richard A.
    Atkinson, Victoria
    Gyorki, David E.
    Lambie, Duncan
    O'Toole, Sandra
    Saw, Robyn P. M.
    Amanuel, Benhur
    Angel, Christopher M.
    Button-Sloan, Alison E.
    Carlino, Matteo S.
    Ch'ng, Sydney
    Colebatch, Andrew J.
    Daneshvar, Dariush
    da Silva, Ines Pires
    Dawson, Tamara
    Ferguson, Peter M.
    Foster-Smith, Erwin
    Fox, Stephen B.
    Gill, Anthony J.
    Gupta, Ruta
    Henderson, Michael A.
    Hong, Angela M.
    Howle, Julie R.
    Jackett, Louise A.
    James, Craig
    Lee, C. Soon
    Lochhead, Alistair
    Loh, Daphne
    McArthur, Grant A.
    McLean, Catriona A.
    Menzies, Alexander M.
    Nieweg, Omgo E.
    O'Brien, Blake H.
    Pennington, Thomas E.
    Potter, Alison J.
    Prakash, Saurabh
    Rawson, Robert, V
    Read, Rebecca L.
    Rtshiladze, Michael A.
    Shannon, Kerwin F.
    Smithers, B. Mark
    Spillane, Andrew J.
    Stretch, Jonathan R.
    Thompson, John F.
    Tucker, Paul
    Varey, Alexander H. R.
    Vilain, Ricardo E.
    Wood, Benjamin A.
    Long, Georgina, V
    PATHOLOGY, 2022, 54 (01) : 6 - 19
  • [50] Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma
    Gebhardt, Christoffer
    Keller, Laura
    Heidrich, Isabel
    Koett, Julian
    Geidel, Glenn
    Abbott, Charles
    Boyle, Sean Michael
    Pugh, Jason
    Chen, Richard
    Simon, Ronald
    Schneider, Stefan W.
    Pantel, Klaus
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)